New vaccine combo takes on tough lung cancer in early trial
NCT ID NCT07614646
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also looking at whether the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EVM14 (cancer vaccine) and ivonescimab (immunotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced squamous non-small cell lung cancer, potentially improving tumor control.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The vaccine may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outperform standard therapy for lung cancer?
- Can a pill help keep advanced lung cancer at bay?
- Can a novel drug combo outperform chemo in lung cancer?
- Can a new drug ASP388B take on advanced solid tumors?
- Could a cheaper copy of keytruda work just as well against cancer?
- New lung cancer cocktail aims to outperform current standard therapy